Why Human Germline Editing Might Never Be Legal in the U.S.
By Jennifer M. Gumer,
The Hastings Center
| 08. 09. 2019
What would it take for the first case of germline editing to proceed under applicable U.S. law and ethical standards?
A Russian scientist recently announced his intention to use the gene-editing tool CRISPR to edit and implant human embryos—a revelation that met with international outcry similar to the condemnation of the Chinese scientist He Jiankui last year when he announced that he had created the first gene-edited babies. Jiankui’s actions — deemed unethical for several reasons – led to a call for a moratorium on editing human germline cells (sperm, eggs, or embryos) to produce genetically modified babies.
Even the signatories of the moratorium, however, suggest that CRISPR might one day be safe enough for ethical, clinical use on the germline. What would it take for the first case of germline editing to proceed under applicable U.S. law and ethical standards?
Germline editing would be regulated as a gene therapy by the Food and Drug Administration. To comply with the relevant regulations, germline editing must undergo clinical testing to demonstrate safety and efficacy and win FDA approval before coming to market. Currently, federal law prevents the FDA from reviewing or approving any application involving manipulated human embryos. However, if...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...